According to the outlet, New York-based Pfizer sold over-the-counter ranitidine drugs also known as Zantac from 1998 through 2006. In 2019, a small laboratory in Connecticut found that ranitidine ...

GSK did not admit wrongdoing as part of the deal, saying in a statement that there was "no consistent or reliable evidence" that ranitidine, the drug's active ingredient, increased the risk of cancer.

The FDA has asked drugmakers to pull all prescription and over-the-counter products based on ranitidine off the market immediately, after a review failed to alleviate concerns about a cancer risk.

Zantac Litigation is Born “The best starting point involves a private company known as Valisure. Valisure theorized that ranitidine [aka Zantac] has the potential to degrade into a carcinogen known as ...

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

Supplies of the heartburn drug ranitidine have been recalled globally following a cancer scare involving multiple pharma companies, where a carcinogenic impurity is suspected to be present in the ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.

GSK did not admit wrongdoing as part of the deal, saying in a statement that there was "no consistent or reliable evidence" ...

Plaintiffs argued that the company knew that Zantac’s active ingredient, ranitidine, turned into the potential carcinogen NDMA under certain conditions. The US Food and Drug Administration asked ...